|

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

RECRUITINGN/ASponsored by Barbara Ann Karmanos Cancer Institute
Actively Recruiting
PhaseN/A
SponsorBarbara Ann Karmanos Cancer Institute
Started2025-08-18
Est. completion2026-08-08
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site

Summary

The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
* Participants must be 18 years of age or older
* Participant must be able to understand a written informed consent document and be willing to sign it
* Participant must be assigned female at birth
* Participant must have a Karnofsky performance score of greater than or equal to 70%
* Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:

  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
  * Agree to practice true abstinence from sexual intercourse
  * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
  * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
* For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6

Exclusion Criteria:

* Participants who have received prior radiation treatment to the affected breast.
* Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
* Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
* Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
* Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Conditions6

Breast CancerCancerDuctal Carcinoma in SituStage I Breast CancerStage II Breast CancerStage III Breast Cancer

Locations1 site

Karmanos Cancer Institute
Detroit, Michigan, 48201
Michael Dominello, DO313-576-9546mdominel@med.wayne.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.